科华生物(002022) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥397,685,696.45, a decrease of 9.96% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥99,080,102.24, representing a decline of 42.20% year-on-year[5]. - The basic earnings per share were -¥0.1926, down 39.77% from the previous year[5]. - Total operating revenue decreased to ¥1,191,260,566.76 from ¥1,350,223,553.61, representing a decline of approximately 11.8% year-over-year[20]. - Net profit for the period was a loss of ¥253,819,970.95, compared to a loss of ¥106,928,544.45 in the previous period, indicating a significant increase in losses[21]. - Basic and diluted earnings per share were both reported at -0.4521, compared to -0.2413 in the previous period[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,170,207,077.81, a decrease of 1.26% from the end of the previous year[5]. - Total assets decreased to ¥5,170,207,077.81 from ¥5,236,128,052.84, reflecting a decline of approximately 1.3%[18]. - Total liabilities increased to ¥1,423,450,649.92 from ¥1,253,747,330.56, marking an increase of about 13.5%[18]. Cash Flow - Cash flow from operating activities for the year-to-date was -¥24,096,981.35, an improvement of 65.46% compared to the same period last year[11]. - Operating cash inflow for the current period was CNY 1,408,569,868.23, a decrease of 8.1% from CNY 1,533,401,815.74 in the previous period[22]. - Net cash flow from operating activities was CNY -24,096,981.35, an improvement from CNY -69,762,194.20 in the previous period[22]. - Cash inflow from investment activities totaled CNY 7,309,152.33, down significantly from CNY 177,920,867.58 in the previous period[22]. - Net cash flow from investment activities was CNY -89,058,866.50, worsening from CNY -4,694,494.96 in the previous period[22]. - Cash inflow from financing activities was CNY 380,789,640.48, an increase from CNY 121,361,311.96 in the previous period[23]. - Net cash flow from financing activities improved to CNY 121,170,122.91 from CNY -664,513,137.74 in the previous period[23]. - The ending cash and cash equivalents balance was CNY 867,784,574.93, slightly up from CNY 861,985,598.59 in the previous period[23]. - The company received CNY 378,539,640.48 in borrowings, a significant increase from CNY 118,075,216.96 in the previous period[23]. - Cash paid for operating activities was CNY 1,432,666,849.58, down from CNY 1,603,164,009.94 in the previous period[22]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 48,108[13]. - The largest shareholder, Zhuhai Baolian Investment Holding Co., Ltd., holds 13.64% of shares, totaling 70,147,179 shares[13]. - The company’s repurchased shares account for 2.66% of the total share capital, amounting to 13,696,600 shares[14]. - The top ten shareholders include both state-owned and private entities, indicating a diverse ownership structure[13]. - The company has signed a voting rights entrustment agreement with its controlling shareholder, affecting 10.64% of the voting rights[13]. Other Financial Metrics - The weighted average return on net assets was -3.11%, a decrease of 1.37 percentage points compared to the previous year[5]. - The company reported a significant increase in short-term borrowings, which rose by 270.91% to ¥309,419,850.98 due to operational needs[10]. - The company experienced a 412.77% increase in other comprehensive income, influenced by changes in the euro exchange rate[10]. - Investment income decreased by 87.70% to ¥1,056,127.82, attributed to lower returns from financial products compared to the previous year[10]. - The company reported a 75.74% increase in credit impairment losses, reflecting higher provisions for bad debts[11]. - Research and development expenses decreased to ¥114,226,587.57 from ¥147,599,126.10, a reduction of about 22.6% year-over-year[21]. - Other comprehensive income after tax was ¥25,828,113.66, compared to a loss of ¥1,734,692.20 in the previous period, indicating a recovery in this area[21]. Audit Information - The company did not undergo an audit for the third quarter financial report[24].